Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorGlobeNewsWire • Thursday
Inventiva: Solid MASH Program With Potential For Strategic Partnership AdvancementSeeking Alpha • 07/08/24
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial positionGlobeNewsWire • 07/05/24
Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024GlobeNewsWire • 06/21/24
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)Zacks Investment Research • 06/18/24
Combined General Meeting of June 20, 2024 - Availability of the preparatory documentsGlobeNewsWire • 05/30/24
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024GlobeNewsWire • 05/22/24
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateGlobeNewsWire • 05/21/24
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASHGlobeNewsWire • 05/16/24
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorGlobeNewsWire • 05/13/24
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FGlobeNewsWire • 04/03/24
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsGlobeNewsWire • 03/22/24
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DGlobeNewsWire • 03/18/24
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DGlobeNewsWire • 03/13/24
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedGlobeNewsWire • 03/07/24
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3GlobeNewsWire • 02/15/24
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment BankGlobeNewsWire • 01/10/24
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development programGlobeNewsWire • 12/20/23
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASHGlobeNewsWire • 12/04/23